OncoMatch/Clinical Trials/NCT06831136
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
Official title: Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation
Is NCT06831136 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Chemotherapy (NAC) and Immunotherapy (pembrolizumab) for pancreatic ductal adenocarcinoma.
Treatment: Neoadjuvant Chemotherapy (NAC) · Immunotherapy (pembrolizumab) · Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) — The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: prior adjuvant/neoadjuvant therapy completed ≥3 months before enrollment; up to 3 months of first-line chemotherapy for mPDAC with stable disease allowed
No prior systemic therapy, including chemotherapy or chemoradiation is permitted with the following exceptions: Prior adjuvant therapy (including chemotherapy and/or radiotherapy) for pancreatic adenocarcinoma is permitted if standard of care neoadjuvant or adjuvant therapy was completed at least 3 months prior to study enrollment. If started on first-line treatment for mPDAC elsewhere, eligible participants can have undergone 3 months of chemotherapy with clinically stable disease before study entry. Patients who have started chemotherapy within a 3-month timeframe are allowed.
Lab requirements
Blood counts
ANC ≥1 x 10^9/L; platelet count ≥75 x 10^9/L
Kidney function
Serum creatinine clearance ≥30 mL/min (measured or Cockcroft-Gault)
Liver function
Total serum bilirubin <2× ULN unless secondary to Gilbert's Syndrome; patients with declining bilirubin post stent eligible with serum bilirubin ≤2.5 x ULN; ALT, AST, ALP ≤3× ULN, or ≤5× ULN with liver involvement; albumin ≥3 g/dL
ANC ≥1 x 10^9/L; Platelet count ≥75 x 10^9/L; Albumin ≥3 g/dL; Total serum bilirubin <2× ULN unless secondary to Gilbert's Syndrome; ALT, AST, ALP ≤3× ULN, or ≤5× ULN with liver involvement; Serum creatinine clearance ≥30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas Health Science Center at Houston · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06831136 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages